Severe Cytokine-Release Syndrome after T Cell–Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti–IL-6 Therapy Is Safe and Well Tolerated

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 10, 2016, Pages 1851-1860

  Abboud, Ramzi ^a   Keller, Jesse ^a   Slade, Michael ^a   DiPersio, John F ^a   Westervelt, Peter ^a   Rettig, Michael P ^a   Meier, Stephanie ^a   Fehniger, Todd A ^a   Abboud, Camille N ^a   Uy, Geoffrey L ^a   Vij, Ravi ^a   Trinkaus, Kathryn M ^a   Schroeder, Mark A ^a   Romee, Rizwan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine release syndrome (CRS); Haploidentical; Tocilizumab; Transplantation related mortality (TRM)

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TOCILIZUMAB; TUMOR NECROSIS FACTOR; CYTOKINE; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT RECIPIENT; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MORTALITY; NEUTROPHIL; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SINGLE DRUG DOSE; T CELL REPLETE PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; HAPLOIDENTICAL TRANSPLANTATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; MIDDLE AGED; PROCEDURES; SURVIVAL ANALYSIS; SYNDROME; T LYMPHOCYTE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-6; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; SYNDROME; T-LYMPHOCYTES; TRANSPLANTATION, HAPLOIDENTICAL; YOUNG ADULT;

EID: 84992055543     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.06.010     Document Type: Article

References (46)

1. 1 Raiola, A.M., Dominietto, A., Ghiso, A., et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19 (2013), 117–122, 10.1016/j.bbmt.2012.08.014.
2. 2 Gragert, L., Eapen, M., Williams, E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371 (2014), 339–348, 10.1056/NEJMsa1311707.
3. 3 Bashey, A., Zhang, X., Sizemore, C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 31 (2013), 1310–1316, 10.1200/JCO.2012.44.3523.
4. 4 Bashey, A., Solomon, S.R., T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant 49 (2014), 999–1008, 10.1038/bmt.2014.62.
5. 5 Kanakry, J.A., Kasamon, Y.L., Gocke, C.D., et al. Outcomes of related donor HLA-Identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 19 (2013), 602–606, 10.1016/j.bbmt.2013.01.006.
6. 6 Luznik, L., O'Donnell, P.V., Fuchs, E.J., Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 39 (2012), 683–693, 10.1053/j.seminoncol.2012.09.005.
7. 7 Luznik, L., O'Donnell, P. V, Symons, H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14 (2008), 641–650, 10.1016/j.bbmt.2008.03.005.
8. 8 Raj, K., Pagliuca, A., Bradstock, K., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 20 (2014), 890–895, 10.1016/j.bbmt.2014.03.003.
9. 9 Bhamidipati, P.K., DiPersio, J.F., Stokerl-Goldstein, K., et al. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 49 (2014), 1124–1126, 10.1038/bmt.2014.108.
10. 10 Anasetti, C., Logan, B.R., Lee, S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367 (2012), 1487–1496, 10.1056/NEJMoa1203517.
11. 11 Couban, S., Simpson, D.R., Barnett, M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002), 1525–1531, 10.1182/blood-2002-01-0048.S.C.
12. 12 Tisoncik, J.R., Korth, M.J., Simmons, C.P., Farrar, J., Martin, T.R., Katze, M.G., Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76 (2012), 16–32, 10.1128/MMBR.05015-11.
13. 13 Lee, D.W., Gardner, R., Porter, D.L., et al. Current concepts in the diagnosis and management of cytokine release syndrome. How I Treat Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195, 10.1182/blood-2014-05-552729.
14. 14 Maude, S.L., Frey, N., Shaw, P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517, 10.1056/NEJMoa1407222.
15. 15 Davila, M.L., Riviere, I., Wang, X., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6, 2014, 224ra25, 10.1126/scitranslmed.3008226.
16. 16 Grupp, S.A., Kalos, M., Barrett, D., et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518, 10.1056/NEJMoa1215134.
17. 17 Suntharalingam, G., Perry, M.R., Ward, S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006), 1018–1028, 10.1056/NEJMoa063842.
18. 18 Teachey, D.T., Rheingold, S.R., Maude, S.L., et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121 (2013), 5154–5157, 10.1182/blood-2013-02-485623.
19. 19 Wing, M.G., Moreau, T., Greenwood, J., et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98 (1996), 2819–2826, 10.1172/jci119110.
20. 20 Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A., Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94 (1999), 2217–2224.
21. 21 Teachey, D.T., Lacey, S.F., Shaw, P.A., et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t cell therapy for acute lymphoblastic leukemia. Cancer Discov, 2016, 10.1158/2159-8290.CD-16-0040.
22. 22 Beloosesky, Y., Hendel, D., Weiss, A., et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol A Biol Sci Med Sci 62 (2007), 420–426.
23. 23 Jules-Elysee, K.M., Wilfred, S.E., Memtsoudis, S.G., et al. Steroid modulation of cytokine release and desmosine levels in bilateral total knee replacement: a prospective, double-blind, randomized controlled tria. J Bone Joint Surg Am 94 (2012), 2120–2127.
24. 24 Kennedy, G.A., Varelias, A., Vuckovic, S., et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 15 (2014), 1451–1459.
25. 25 Solomon, S.R., Sizemore, C.A., Sanacore, M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival. Biol Blood Marrow Transplant 18 (2012), 1859–1866, 10.1016/j.bbmt.2012.06.019.
26. 26 Chen, Y., Huang, X.-J., Wang, Y., et al. Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. Transfusion 55 (2015), 2023–2031, 10.1111/trf.13167.
27. 27 Chen, Y., Huang, X.-J., Liu, K.-Y., et al. Infusion-related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graft-versus-host disease. Pediatr Transplant, 2015, 10.1111/petr.12586.
28. 28 O'Donnell, P., Raj, K., Pagliuca, A., High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 21 (2015), 197–198, 10.1016/j.bbmt.2014.10.008.
29. 29 Colvin, G.A., Berz, D., Ramanathan, M., et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 15 (2009), 421–431, 10.1016/j.bbmt.2008.12.503.
30. 30 Spitzer, T.R., Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant 50 (2015), 469–475, 10.1038/bmt.2014.296.
31. 31 Przepiorka, D., Weisdorf, D., Martin, P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995), 825–828.
32. 32 Sullivan, K.M., Shulman, H.M., Storb, R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57 (1981), 267–276.
33. 33 Sorror, M.L., Maris, M.B., Storb, R., et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005), 2912–2919, 10.1182/blood-2005-05-2004.Supported.
34. 34 Porter, D.L., Lacey, S.F., Hwang, W.-T., et al. Cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) CLL. Blood, 124, 2014.
35. 35 Solomon, S.R., Sizemore, C.A., Sanacore, M., et al. Total body irradiation–based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patientswithout matched sibling donors. Biol Blood Marrow Transplant 21 (2015), 1299–1307, 10.1016/j.bbmt.2015.03.003.
36. 36 Castagna, L., Crocchiolo, R., Furst, S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 20 (2014), 724–729, 10.1016/j.bbmt.2014.02.001.
37. 37 Ciurea, S.O., Mulanovich, V., Saliba, R.M., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18 (2012), 1835–1844, 10.1016/j.bbmt.2012.07.003.
38. 38 Kasamon, Y.L., Luznik, L., Leffell, M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16 (2010), 482–489, 10.1016/j.bbmt.2009.11.011.Nonmyeloablative.
39. 39 Grosso, D., Gaballa, S., Alpdogan, O., et al. A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol Blood Marrow Transplant 21 (2015), 646–652, 10.1016/j.bbmt.2014.12.019.
40. 40 Grosso, D., Carabasi, M., Filicko-O'Hara, J., et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 118 (2011), 4732–4739, 10.1182/blood-2011-07-365338.
41. 41 Vasu, S., Geyer, S., Bingman, A., et al. Granulocyte colony-stimulating factor–mobilized allografts contain activated immune cell subsets associated with risk of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant, 2015, 1–11, 10.1016/j.bbmt.2015.12.015.
42. 42 Broxmeyer, H.E., Williams, D.E., Lu, L., et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 136 (1986), 4487–4495.
43. 43 Oehler, L., Foedinger, M., Koeller, M., et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood 89 (1997), 1147–1153.
44. 44 Sato, T., Misago, M., Tsukada, J., et al. Effect of interleukin-4 on the growth of granulocyte-macrophage progenitor cells stimulated by hematopoietic growth factors. J UOEH 12 (1990), 163–174.
45. 45 Katayama, K., Koizumi, S., Ueno, Y., et al. Antagonistic effects of interleukin 6 and G-CSF in the later stage of human granulopoiesis in vitro. Exp Hematol 18 (1990), 390–394.
46. 46 Chen, F., Teachey, D.T., Pequignot, E., et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods, 2016, 10.1016/j.jim.2016.03.005.